MTOR and pneumonitis: Although several studies now show improved pulmonary function with sirolimus treatment, it is not clear that that long term benefits will outweigh risks, especially considering that sirolimus is an immunosuppressant and pneumonitis is a known and potentially serious toxicity of mTOR inhibitors [32], [47].